Drugs / HD1916
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06604624 | Sep 2024 → Aug 2025 | — | CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HD1916 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06604624 ↗ |
| Route | Subcutaneous | “HD1916 will be administered via subcutaneous injection once a week in subjects with obesity.” NCT06604624 ↗ |